POLB.LSE Poolbeg Pharma PLC
- Market cap
- GBX 48.8M
- P/E
- -
- P/B
- 7.40x
- ROE
- -115.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is POLB.LSE undervalued?
Graham numberThe Graham number of Poolbeg Pharma PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Poolbeg Pharma PLC fundamental analysis
No fundamental analysis for Poolbeg Pharma PLC yet.
Poolbeg Pharma PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza …
Full company profilePoolbeg Pharma PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Poolbeg Pharma PLC annual financial statements
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -18.0K | -26.0K | -26.0K | -114K | -59.0K | -148K |
| Operating Income | -2.38M | -4.99M | -5.04M | -6.62M | -6.42M | -8.84M |
| EBITDA | -2.32M | -4.75M | -4.66M | -6.00M | -6.36M | -8.70M |
| Net Income | -2.34M | -4.69M | -3.93M | -5.79M | -5.70M | -7.76M |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||
| Total Assets | 23.0M | 19.3M | 15.4M | 10.2M | 9.94M | 7.15M |
| Total Liabilities | 438K | 966K | 986K | 974K | 1.34M | 439K |
| Shareholders' Equity | 22.6M | 18.3M | 14.4M | 9.27M | 8.60M | 6.71M |
| Cash & Short-term Investments | 20.9M | 16.2M | 12.2M | 7.82M | 7.71M | 4.82M |
| Cash Flow | ||||||
| Operating Cash Flow | -2.15M | -4.37M | -4.38M | -4.65M | -4.51M | -11.4M |
| Capital Expenditure | 81.0K | 597K | 175K | 129K | 4.51M | 0.00 |
| Free Cash Flow | -2.23M | -4.97M | -4.02M | -4.78M | -4.84M | -11.4M |
| Ratios | ||||||
| ROE | -10.3% | -25.6% | -27.2% | -62.4% | -66.2% | -115.6% |
| ROA | -10.1% | -24.3% | -25.5% | -56.5% | -57.3% | -108.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Poolbeg Pharma PLC dividends
Poolbeg Pharma PLC has not paid dividends in the last 5 fiscal years.
Who owns Poolbeg Pharma PLC
- Insiders 38.76%
- Institutions 4.01%
- Public & others 57.23%
- Shares outstanding 763M
- Free float 514M
Poolbeg Pharma PLC company profile
- Company name
- Poolbeg Pharma PLC
- Ticker
- POLB.LSE
- ISIN
- GB00BKPG7Z60
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- The Clubhouse Holborn, London, United Kingdom, EC4A 3AG
- Phone
- 44 20 7183 1499
- Website
- poolbegpharma.com
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.
Poolbeg Pharma PLC management
6- Mr. Cathal Martin FrielExecutive Chairman of The Board · born 1964
- Dr. Jeremy Skillington Ph.D.CEO & Director · born 1971
- Mr. Ian O'ConnellCFO & Director · born 1987
- Carol DaltonVice President of Investor Relations & Public Relations
- Mr. Liam TremblePrincipal Scientist
- Mr. Ross CrockettGroup Financial Controller